By Fineline Cube 
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has entered into a strategic partnership with Henan Hualong Biological Co., Ltd., a leading provider of stem cell storage and cell therapy technology services. This collaboration aims to advance the development of multi-activated T lymphocytes (MATC) therapy.
Partnership Details
Under the terms of the agreement, Porton Pharma Solutions will provide comprehensive services ranging from process optimization to regulatory filings for Hualong’s MATC therapy. This one-stop service model underscores Porton’s commitment to supporting innovative cell therapy technologies and accelerating their path to market.
Commitment to Innovation
Porton Pharma Solutions, with its extensive expertise in process optimization and regulatory affairs, is well-positioned to assist Henan Hualong in navigating the complexities of bringing cutting-edge cell therapies to patients in need.-Fineline Info & Tech